Notably, the inhibition of IL-23 does not interfere with the normal physiological roles of other cytokines, such as IL-17, derived from different cellular sources, making IL-23 a highly attractive therapeutic target for psoriasis. This evidence concerns the gene IL17A and psoriasis.